P-selectin is an adhesion molecule involved in the interactions between endothelial cells, platelets and leukocytes. Inclacumab is a recombinant monoclonal antibody against P-selectin, a potential anti-inflammatory, anti-thrombotic and anti-atherogenic.
The objective of the SELECT-ACS was to evaluate whether Inclacumab could reduce myocardial damage during percutaneous coronary intervention (PCI) in patients with non-ST elevation myocardial infarction (NSTEMI). We included 544 patients with NSTEMI scheduled for coronary angiography and possible angioplasty “ad hoc” to receive an infusion of Inclacumab, 5 or 20 mg/kg versus a placebo.
The incidence of CK-MB> 3 times the upper limit of normal within 24 hours was 18.3% in the Inclacumab group, 20 mg/kg (p = 0.05) and 8.9% in the placebo group. No significant differences in adverse events between groups were observed. On this basis, the authors reported that Inclacumab appears to reduce myocardial damage after PCI in patients with NSTEMI.
Jean Claude Tardif
2013-03-12
Original title: Effects of the P-Selectin Antagonist Inclacumab in the Select-Acute Coronary Syndromes Trial.
